|
1.
|
Sylvester RJ, van der Meijden AP,
Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and
Kurth K: Predicting recurrence and progression in individual
patients with stage Ta T1 bladder cancer using EORTC risk tables: a
combined analysis of 2596 patients from seven EORTC trials. Eur
Urol. 49:466–465. 2006. View Article : Google Scholar
|
|
2.
|
Witjes JA: Management of BCG failures in
superficial bladder cancer: a review. Eur Urol. 49:790–797. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Punnen SP, Chin JL and Jewett MA:
Management of bacillus Calmette-Guerin (BCG) refractory superficial
bladder cancer: results with intravesical BCG and Interferon
combination therapy. Can J Urol. 10:1790–1795. 2003.
|
|
4.
|
Kim JC and Steinberg GD: Medical
management of patients with refractory carcinoma in situ of the
bladder. Drugs Aging. 18:335–344. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Herr HW, Wartinger DD, Fair WR and Oettgen
HF: Bacillus Calmette-Guerin therapy for superficial bladder
cancer: a 10-year followup. J Urol. 147:1020–1023. 1992.PubMed/NCBI
|
|
6.
|
Esuvaranathan K, Chiong E, Thamboo TP,
Chan YH, Kamaraj R, Mahendran R and Teh M: Predictive value of p53
and pRb expression in superficial bladder cancer patients treated
with BCG and interferon-alpha. Cancer. 109:1097–1105. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Huguet J, Crego M, Sabate S, Salvador J,
Palou J and Villavicencio H: Cystectomy in patients with high risk
superficial bladder tumours who fail intravesical BCG therapy:
pre-cystectomy prostate involvement as a prognostic factor. Eur
Urol. 48:53–59. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Ahirwar D, Kesarwani P, Manchanda PK,
Mandhani A and Mittal RD: Anti- and proinflammatory cytokine gene
polymorphism and genetic predisposition: association with smoking,
tumor stage and grade, and bacillus Calmette-Guérin immunotherapy
in bladder cancer. Cancer Genet Cytogenet. 184:1–8. 2008.PubMed/NCBI
|
|
9.
|
Cai T, Nesi G, Dal Canto M, Tinacci G,
Mondaini N, Piazzini M, Geppetti P and Bartoletti R: Loss of
heterozygosis on IFN-alpha locus is a prognostic indicator of
bacillus Calmette-Guerin response for nonmuscle invasive bladder
cancer. J Urol. 183:1738–1743. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Zhang Y, Mahendran R, Yap LL,
Esuvaranathan K and Khoo HE: The signalling pathway for BCG-induced
interleukin-6 production in human bladder cancer cells. Biochem
Pharmacol. 63:273–282. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Luo Y, Han R, Evanoff DP and Chen X:
Interleukin-10 inhibits Mycobacterium bovis bacillus
Calmette-Guérin (BCG)-induced macrophage cytotoxicity against
bladder cancer cells. Clin Exp Immunol. 160:359–368. 2010.
|
|
12.
|
Chen FH, Crist SA, Zhang GJ, Iwamoto Y and
See WA: Interleukin-6 production by human bladder tumor cell lines
is up-regulated by bacillus Calmette-Guérin through nuclear
factor-kappaB and Ap-1 via an immediate early pathway. J Urol.
168:786–97. 2002.PubMed/NCBI
|
|
13.
|
Oosterlinck W, Lobel B, Jakse G, Malmström
P, Stöckle M and Sternberg C; European Association of Urology (EAU)
Working Group on Oncological Urology: Guidelines on bladder cancer.
Eur Urol. 41:105–112. 2002. View Article : Google Scholar
|
|
14.
|
Herr HW and Dalbagni G: Defining bacillus
Calmette-Guerin refractory superficial bladder tumors. J Urol.
169:1706–1708. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Thalmann GN, Markwalder R, Shahin O,
Burkhard FC, Hochreiter WW and Studer UE: Primary T1G3 bladder
cancer: organ preserving approach or immediate cystectomy? J Urol.
172:70–75. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Cai T, Nesi G, Tinacci G, Zini E, Mondaini
N, Boddi V, Mazzoli S and Bartoletti R: Can early single dose
instillation of epirubicin improve bacillus Calmette-Guerin
efficacy in patients with nonmuscle invasive high risk bladder
cancer? Results from a prospective, randomized, double-blind
controlled study. J Urol. 180:110–115. 2008. View Article : Google Scholar
|
|
17.
|
Lamm DL and Crawford ED, Blumenstein B,
Crismann JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD,
Grossman HB, Beck TM, Leimers JT and Crawford ED: Maintenance BCG
immunotherapy for recurrent Ta, T1 and Tis transitional cell
carcinoma of the bladder: a randomized prospective Southwest
Oncology Group study. J Urol. 163:1124–1129. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Cai T, Mazzoli S, Meacci F, Nesi G,
Geppetti P, Malossini G and Bartoletti R: Human papillomavirus and
non-muscle invasive urothelial bladder cancer: Potential
relationship from a pilot study. Oncol Rep. 25:485–489.
2011.PubMed/NCBI
|
|
19.
|
Cai T, Piazzini M, Nesi G, Taddei I, Sardi
I, Detti B, Mondaini N, Dal Canto M and Bartoletti R: E-cadherin
mRNA expression analysis in evaluating the natural history of
urothelial bladder cell carcinoma: Results from a long-term
follow-up study. Oncol Rep. 17:925–930. 2007.PubMed/NCBI
|
|
20.
|
Thalmann GN, Sermier A, Rentsch C, Mohrle
K, Cecchini MG and Studer UE: Urinary interleukin-8 and 18 predict
the response of superficial bladder cancer to intravesical therapy
with bacillus Calmette-Guerin. J Urol. 164:2129–2133. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Watanabe E, Matsuyama H, Matsuda K, Ohmi
C, Tei Y, Yoshihiro S, Ohmoto Y and Naito K: Urinary interleukin-2
may predict clinical outcome of intravesical bacillus
Calmette-Guerin immunotherapy for carcinoma in situ of the bladder.
Cancer Immunol Immunother. 52:481–486. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Barton BE: Interleukin-6 and new
strategies for the treatment of cancer, hyperproliferative diseases
and paraneoplastic syndromes. Expert Opin Ther Targets. 9:737–752.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Liang B, Gardner DB, Griswold DE, Bugelski
PJ and Song X: Anti-interleukin-6 monoclonal antibody inhibits
autoimmune responses in a murine model of systemic lupus
erythematosus. Immunology. 119:296–305. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Seguchi T, Yokokawa K, Sugao H, Nakano E,
Sonoda T and Okuyama A: Interleukin-6 activity in urine and serum
in patients with bladder carcinoma. J Urol. 148:791–794.
1992.PubMed/NCBI
|
|
25.
|
Mulé JJ, McIntosh JK, Jablons DM and
Rosenberg SA: Antitumor activity of recombinant interleukin 6 in
mice. J Exp Med. 171:629–636. 1990.
|
|
26.
|
Sabat R and Asadullah K: Interleukin-10 in
cancer immunity. Cancer Immune Therapy: Experiences and Future
Strategies. Stuhler G and Walden P: Wiley-VCH Verlag GmbH;
Weinheim, Germany: pp. 223–231. 2002
|
|
27.
|
Nadler R, Luo Y, Zhao W, Ritchey JK,
Austin JC, Cohen MB, O’Donnell MA and Ratliff TL: Interleukin 10
induced augmentation of delayed-type hypersensitivity (DTH)
enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG)
mediated antitumour activity. Clin Exp Immunol. 131:206–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Agarwal A, Verma S, Burra U, Murthy NS,
Mohanty NK and Saxena S: Flow cytometric analysis of Th1 and Th2
cytokines in PBMCs as a parameter of immunological dysfunction in
patients of superficial transitional cell carcinoma of bladder.
Cancer Immunol Immunother. 55:734–743. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Suttmann H, Jacobsen M, Reiss K, Jocham D,
Bohle A and Brandau S: Mechanisms of bacillus Calmette-Guerin
mediated natural killer cell activation. J Urol. 172:1490–1495.
2004. View Article : Google Scholar : PubMed/NCBI
|
